IL161310A0 - Use of a substance signaling through gp 130 in pns disorders - Google Patents
Use of a substance signaling through gp 130 in pns disordersInfo
- Publication number
- IL161310A0 IL161310A0 IL16131002A IL16131002A IL161310A0 IL 161310 A0 IL161310 A0 IL 161310A0 IL 16131002 A IL16131002 A IL 16131002A IL 16131002 A IL16131002 A IL 16131002A IL 161310 A0 IL161310 A0 IL 161310A0
- Authority
- IL
- Israel
- Prior art keywords
- pns disorders
- substance signaling
- signaling
- substance
- pns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01123400 | 2001-10-11 | ||
PCT/EP2002/011364 WO2003033015A1 (en) | 2001-10-11 | 2002-10-10 | USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161310A0 true IL161310A0 (en) | 2004-09-27 |
Family
ID=8178778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16131002A IL161310A0 (en) | 2001-10-11 | 2002-10-10 | Use of a substance signaling through gp 130 in pns disorders |
Country Status (20)
Country | Link |
---|---|
US (3) | US7465441B2 (xx) |
EP (1) | EP1434597B1 (xx) |
JP (1) | JP2005505608A (xx) |
KR (1) | KR20050035151A (xx) |
CN (1) | CN1602203A (xx) |
AT (1) | ATE542542T1 (xx) |
AU (1) | AU2002340547B2 (xx) |
BR (1) | BR0213183A (xx) |
CA (1) | CA2463020A1 (xx) |
DK (1) | DK1434597T3 (xx) |
EA (1) | EA006881B1 (xx) |
ES (1) | ES2381341T3 (xx) |
HR (1) | HRP20040292A2 (xx) |
IL (1) | IL161310A0 (xx) |
MX (1) | MXPA04003442A (xx) |
NO (1) | NO20041908L (xx) |
PL (1) | PL369296A1 (xx) |
WO (1) | WO2003033015A1 (xx) |
YU (1) | YU29804A (xx) |
ZA (1) | ZA200402351B (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2463020A1 (en) * | 2001-10-11 | 2003-04-24 | Applied Research Systems Ars Holding N.V. | Use of gp130 activators in diabetic neuropathy |
SI1622939T1 (sl) | 2003-05-13 | 2012-06-29 | Merck Serono Sa | Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega |
AU2011203356B2 (en) * | 2004-04-29 | 2012-03-22 | Yeda Research & Development Co., Ltd | IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy |
IL161673A0 (en) | 2004-04-29 | 2004-09-27 | Applied Research Systems | Compositions and methods for therapy of chemotherapy-induced neuropathy |
IL161672A0 (en) | 2004-04-29 | 2004-09-27 | Yeda Res & Dev | Compositions and methods for therapy of chemotherapy-induced neuropathy |
IL163856A0 (en) * | 2004-09-01 | 2005-12-18 | Applied Research Systems | Use of IL-6 in vascular complications |
CA2681935A1 (en) * | 2007-03-30 | 2008-10-09 | Baker Medical Research Institute | Treatment of obesity |
DE102008057867A1 (de) * | 2008-11-18 | 2010-05-20 | B. Braun Melsungen Ag | Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten |
CN106924736B (zh) * | 2017-05-09 | 2020-01-03 | 北京师范大学 | gp130抑制剂在制备干预和治疗肥胖导致的血糖代谢疾病产品中的应用 |
FR3080533A1 (fr) * | 2018-04-27 | 2019-11-01 | Enterosys | Utilisation de l'il-6 pour le traitement du diabete |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849571A (en) * | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5300292A (en) * | 1991-05-03 | 1994-04-05 | The Regents Of The University Of California | Composition and method for treating inflammation |
IT1261787B (it) | 1993-06-23 | 1996-06-03 | Angeletti P Ist Richerche Bio | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. |
US6479258B1 (en) * | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5741772A (en) * | 1997-02-03 | 1998-04-21 | Amgen Inc. | Neurotrophic factor NNT-1 |
US7754855B1 (en) * | 1999-07-13 | 2010-07-13 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
CA2463020A1 (en) * | 2001-10-11 | 2003-04-24 | Applied Research Systems Ars Holding N.V. | Use of gp130 activators in diabetic neuropathy |
-
2002
- 2002-10-10 CA CA002463020A patent/CA2463020A1/en not_active Abandoned
- 2002-10-10 AT AT02774697T patent/ATE542542T1/de active
- 2002-10-10 ES ES02774697T patent/ES2381341T3/es not_active Expired - Lifetime
- 2002-10-10 EA EA200400520A patent/EA006881B1/ru not_active IP Right Cessation
- 2002-10-10 IL IL16131002A patent/IL161310A0/xx unknown
- 2002-10-10 YU YU29804A patent/YU29804A/sh unknown
- 2002-10-10 MX MXPA04003442A patent/MXPA04003442A/es unknown
- 2002-10-10 DK DK02774697.3T patent/DK1434597T3/da active
- 2002-10-10 JP JP2003535817A patent/JP2005505608A/ja active Pending
- 2002-10-10 EP EP02774697A patent/EP1434597B1/en not_active Expired - Lifetime
- 2002-10-10 BR BR0213183-8A patent/BR0213183A/pt not_active IP Right Cessation
- 2002-10-10 PL PL02369296A patent/PL369296A1/xx not_active Application Discontinuation
- 2002-10-10 WO PCT/EP2002/011364 patent/WO2003033015A1/en active Application Filing
- 2002-10-10 AU AU2002340547A patent/AU2002340547B2/en not_active Ceased
- 2002-10-10 US US10/492,087 patent/US7465441B2/en not_active Expired - Lifetime
- 2002-10-10 CN CNA028247272A patent/CN1602203A/zh active Pending
- 2002-10-10 KR KR1020047005334A patent/KR20050035151A/ko not_active Application Discontinuation
-
2004
- 2004-03-25 HR HR20040292A patent/HRP20040292A2/hr not_active Application Discontinuation
- 2004-03-25 ZA ZA200402351A patent/ZA200402351B/en unknown
- 2004-05-10 NO NO20041908A patent/NO20041908L/no not_active Application Discontinuation
-
2008
- 2008-12-16 US US12/336,161 patent/US20090169506A1/en not_active Abandoned
-
2010
- 2010-04-05 US US12/754,335 patent/US8278286B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NO20041908L (no) | 2004-05-10 |
US20090169506A1 (en) | 2009-07-02 |
ES2381341T3 (es) | 2012-05-25 |
CN1602203A (zh) | 2005-03-30 |
US20100189684A1 (en) | 2010-07-29 |
AU2002340547B2 (en) | 2008-04-03 |
HRP20040292A2 (en) | 2005-06-30 |
PL369296A1 (en) | 2005-04-18 |
EP1434597B1 (en) | 2012-01-25 |
EA200400520A1 (ru) | 2004-08-26 |
YU29804A (sh) | 2006-08-17 |
EP1434597A1 (en) | 2004-07-07 |
ATE542542T1 (de) | 2012-02-15 |
BR0213183A (pt) | 2004-08-31 |
US20050058623A1 (en) | 2005-03-17 |
EA006881B1 (ru) | 2006-04-28 |
CA2463020A1 (en) | 2003-04-24 |
KR20050035151A (ko) | 2005-04-15 |
US7465441B2 (en) | 2008-12-16 |
DK1434597T3 (da) | 2012-02-27 |
US8278286B2 (en) | 2012-10-02 |
ZA200402351B (en) | 2005-03-29 |
JP2005505608A (ja) | 2005-02-24 |
MXPA04003442A (es) | 2004-07-08 |
WO2003033015A1 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
YU30004A (sh) | Upotreba flibanserina u lečenju seksualnih poremećaja | |
MY129422A (en) | Medicinal compounds | |
WO2004014953A3 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
WO2003044021A3 (en) | Substituted indolizine-like compounds and methods of use | |
GB0111186D0 (en) | Novel compounds | |
DOP2002000429A (es) | Imidazotriazinas | |
YU37602A (sh) | Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
BR0209812A (pt) | Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas | |
MXPA03005340A (es) | Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida. | |
IL161310A0 (en) | Use of a substance signaling through gp 130 in pns disorders | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
IL168308A (en) | Compositions containing roflumilast and formoterol | |
IL159993A0 (en) | Platinum complexes and their use in cancer treatment | |
IL162482A (en) | Use of the il6 – r / il – 6 chimera in the manufacture of a drug for the treatment of neuronal loss | |
IL147188A (en) | Use of il6ril6 chimera in the manufacture of a remedy for neurological diseases | |
GR1002471B (el) | Πιπεραζινκαρβοξυλικο οξυ,η παρασκευη του και φαρμακευτικες συνθεσεις που το περιεχουν. | |
HUP0401634A2 (hu) | LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására | |
MXPA04001205A (es) | Compuesto para eliminar y/o mitigar la anhedonia. | |
AU9184901A (en) | Use of il-6r/il-6 chimera in huntington's disease | |
MXPA03008406A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina. | |
WO2003000269A3 (de) | Neue verwendung für pde 10a-inhibitoren | |
EA200100876A3 (ru) | Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12 |